Related Experiment Video

Updated: Jan 31, 2026

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

6.1K

Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype

Mirna Swayden1, Juan Iovanna1, Philippe Soubeyran1

  • 1Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, Marseille, France.

Heliyon
|December 25, 2018
PubMed

Insights

Pancreatic Ductal Adenocarcinoma (PDAC) resistance to therapy stems from non-genetic factors, not just mutations. Understanding these phenotypic changes is key to overcoming treatment challenges in this deadly cancer.

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Research

Background:

  • Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal cancer with significant therapeutic resistance.
  • Genetic alterations drive PDAC initiation and heterogeneity but inadequately predict treatment response.
  • Tumor resistance and therapeutic escape in PDAC involve factors beyond genetic profiles.

Purpose of the Study:

  • To review major non-genetic, phenotypic alterations contributing to PDAC treatment resistance.
  • To highlight factors independent of genetic profiles that influence therapeutic outcomes.
  • To provide insights into overcoming resistance mechanisms in pancreatic cancer.

Main Methods:

  • Literature review of phenotypic alterations in PDAC.
  • Analysis of non-genetic factors influencing treatment resistance.
  • Synthesis of current knowledge on therapeutic escape mechanisms.

Main Results:

  • PDAC cells exhibit phenotypic changes that confer resistance to conventional therapies.
  • Micro-environmental factors significantly contribute to acquired drug resistance.
  • Non-genetic alterations are crucial drivers of therapeutic failure in PDAC.

Conclusions:

  • Phenotypic and micro-environmental factors are critical determinants of PDAC treatment resistance.
  • Targeting non-genetic alterations may offer new therapeutic strategies for pancreatic cancer.
  • Further research into these factors is essential for improving patient outcomes.
Keywords:
Cancer researchCell biologyMolecular biologyOncology

More Related Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

14.2K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

13.5K

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K